rPOC-752 / Exuma Biotech - LARVOL DELTA

Generation of tertiary lymphoid structures and CD3+ CD8+ CD56+ NKG2D+ CAR TaNK cells following subcutaneous injection of CD3-directed lentiviral-loaded PBMCs (AACR 2022) - "The subcutaneous injection of CD3-directed LV-loaded PBMCs leads to the formation of tertiary lymphoid structures at the site of injection and the development of distinct CD3+ CD8+ CD56+ NKG2D+ CAR-TaNK cells. These cells possess enhanced systemic proliferative capacity compared to traditional ex vivo manufactured 41BB CAR-T cells in a lymphoreplete mouse model and the ability to eliminate target cells in vivo with low numbers of starting cells (10,000 cells)."

IO biomarker • Oncology • CD19 • CD20 • CD22 • CD4 • CD68 • CD8 • NCAM1 • NKG2D

EXUMA Biotech to Present Preclinical Data from its Subcutaneous CAR-TaNK and In Vivo CAR Cell and Gene Therapy Programs at the American Association for Cancer Research Annual Meeting (PRNewswire) - "EXUMA Biotech, Corp...announced that preclinical data from its novel, subcutaneous CAR-TaNK therapy for hematological tumors, and in vivo engineered CAR gene therapy program (GCAR), will be presented in two posters at the American Association for Cancer Research (AACR) Annual Meeting 2022, taking place April 8-13, in New Orleans, LA."

Preclinical • Hematological Malignancies • Oncology

EXUMA Biotech Completes Series B2 to Advance Novel Cell & Gene Therapies (PRNewswire) - "Proceeds will be used to support further development of EXUMA's autologous subcutaneous rPOC CAR-TaNK (T- and NK-like) platform for hematologic and solid tumors and continued clinical investigation of its Tumor Metabolism Regulated (TMR) CAR technology targeting solid tumors."

Commercial • Hematological Malignancies • Oncology • Solid Tumor

EXUMA Biotech Completes Series B2 to Advance Novel Cell & Gene Therapies (PRNewswire) - "EXUMA Biotech, Corp...announced the completion of a $41 million Series B2 financing. The Series B2 brings the total capital raised since its inception to approximately $130 million....Proceeds will be used to support further development of EXUMA's autologous subcutaneous rPOC CAR-TaNK (T- and NK-like) platform for hematologic and solid tumors and continued clinical investigation of its Tumor Metabolism Regulated (TMR) CAR technology targeting solid tumors."

Financing • Oncology • Solid Tumor